Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23910454 | 0.88 | MAPK1 (0.35) | DAO | |
| SCHEMBL24006871 | 0.77 | CYP2D6 (0.35) | DAO | |
| SCHEMBL25373494 | 0.76 | HCAR3 (0.33) | DAO | |
| SCHEMBL17239455 | 0.72 | — | — | |
| SCHEMBL14718543 | 0.71 | DAO (0.39) | DAO | |
| SCHEMBL24711576 | 0.69 | NOS1 (0.30) | — | |
| SCHEMBL17950341 | 0.68 | — | — | |
| SCHEMBL14723143 | 0.68 | DAO (0.39) | DAO | |
| SCHEMBL14688686 | 0.67 | LMNA (0.41) | — | |
| Hydrochloric Acid SCHEMBL17942045 | 0.67 | TDP1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279016-A1 | Tetrahydropyrazolopyrimidines and Related Analogs for Inhibiting YAP/TAZ-TEAD | CISTIM LEUVEN VZW (BE) | 2023-09-07 | — | — | US | disclosed |
| US-20230279016-A1 | Tetrahydropyrazolopyrimidines and Related Analogs for Inhibiting YAP/TAZ-TEAD | CISTIM LEUVEN VZW (BE) | 2023-09-07 | — | — | US | disclosed |
| WO-2023122783-A2 | TETRAHYDROPYRAZOLOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
| US-20230146395-A1 | Substituted Pyrimidines and Uses Thereof | Verge Analytics, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146395-A1 | Substituted Pyrimidines and Uses Thereof | Verge Analytics, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146395-A1 | Substituted Pyrimidines and Uses Thereof | Verge Analytics, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4118087-A1 | SUBSTITUTED FURO[3,2-D]PYRIMIDINES AND USES THEREOF | Verge Analytics, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| WO-2022261068-A1 | METHODS AND TREATMENT OF VIRAL INFECTION WITH SUBSTITUTED FURO-PYRIMIDINES | Verge Analytics, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261068-A1 | METHODS AND TREATMENT OF VIRAL INFECTION WITH SUBSTITUTED FURO-PYRIMIDINES | Verge Analytics, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2021183439-A1 | SUBSTITUTED FURO[3,2-D]PYRIMIDINES AND USES THEREOF | Verge Analytics, Inc. (US) | 2021-09-16 | — | — | WO | disclosed |
| US-8445676-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110294816-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA R&D (SE) | 2010-06-17 | — | — | US | disclosed |
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| CN-1905884-A | Pyrazole derivatives as inhibitors of receptor tyrosyne kinases | ASTRAZENECA AB (SE) | 2007-01-31 | — | — | CN | disclosed |
| EP-1686999-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049033-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | LTK, ERBB2, ERBB3 | DAO 2955/4885GRIN2B 955/4885 |
| US-20110294816-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, CSNK2A1, CSNK2A2 | DAO 3577/4885GRIN2B 2772/4885 |
| US-20230146395-A1 | Substituted Pyrimidines and Uses Thereof | PIKFYVE, PIK3CA, PIK3CB | DAO 2207/4885GRIN2B 1062/4885 |
| US-20230279016-A1 | Tetrahydropyrazolopyrimidines and Related Analogs for Inhibiting YAP/TAZ-TEAD | YAP1, TEAD2, TEAD1 | DAO 3590/4885GRIN2B 4540/4885 |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | PRKDC, MUSK, LTK | DAO 2727/4885GRIN2B 1259/4885 |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | DAO 4246/4885GRIN2B 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.